AML patients with IDH1/2 mutations treated with venetoclax combined with either HMA or LDAC showed higher CR/CRi rates (56–89%) than the overall patient cohort (50–71%) (Table 3) [31,37,38,39,40,41,48,50,52,54,74]. Here, IDH1 is linked to acute myeloid leukemia.